Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:10
  • preuzimanja u poslednjih 30 dana:4

Sadržaj

članak: 5 od 5  
Back povratak na rezultate
2019, vol. 35, br. 79, str. 1936-1944
Sekretorni leukocitni inhibitor proteaze i njegova uloga u nastanku karcinoma glave i vrata
aDepartment of Oral Medicine and Radiology, A B Shetty Memorial Institute of Dental Sciences, University Nitte, Mangalore, Karnataka, India
bDepartment of Microbiology, K S Hegde Medical Academy, Nitte Deemed To Be University, Mangalore, Karnataka, India

e-adresaajila_v@yahoo.com
Ključne reči: sekretorni inhibitor leukocitne proteaze; Humani Papilloma virus; Epstein Barr virus; Herpes simplex virus; oralni karcinom
Sažetak
Uvod: Oralni karcinom skvamoznih c'elija (OSCC) je najčešc'i zloc'udni tumor i čini preko 90% oralnih karcinoma. Iako je konzumiranje duvana u raznim oblicima glavni etiološki agens, danas je učestalost karcinoma izazvanih virusom u porastu. Humani sekretorni inhibitor leukocitne proteaze (SLPI) je član (urođenih) proteina povezanih sa imunitetom. Ima raznovrsna dejstva uključujuc'i antiinflamatorno, antibakterijsko, antifungalno i antivirusno. SLPI je identifikovan kao jedini najsnažniji faktor u sprečavanju prenosa HIV-1 kroz oralnu sekreciju. Studije su nedavno pokazale njegov efekat protiv virusom izazvanih oralnih karcinoma. Najčešc'e proučavani virusi u oralnoj onkogenezi uključuju Humani Papilloma virus, Epstein Barr virus i Herpes simplex virus. SLPI je pokazao inverznu korelaciju sa pojavom HPV-pozitivnih tumora. U prisustvu HSV infekcije postoji smanjena regulacija SLPI. Smanjen SLPI je zabeležen u Epstein Barr virus povezanom nazofaringealnom karcinomu. Ovaj informativnii članak razmatra različite efekte SLPI sa posebnim fokusom na njegove efekte na virus humane imunodeficijencije-HIV, Humani Papilloma virus, Herpes simplex virus i Epstein Barr virus. Zaključak: Povec'ana SLPI ima zaštitnu ulogu u virusnoj onkogenezi, dok smanjeni nivoi povec'avaju verovatnoc'u virusne infekcije.
Reference
Ashcroft, G.S., Lei, K., Jin, W., Longenecker, G.W., Kulkarni, A.B., Greenwell-Wild, T.B., Hale-Donze, H., McGrady, G., Song, X., Wahl, S.M. (2000) Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nature Medicine, 6(10): 1147-1153
Devoogdt, N., Revets, H., Ghassabeh, G.H., de Baetselier, P. (2004) Secretory leukocyte protease inhibitor in cancer development. Ann N Y Acad Sci, 1028: 380-389
Devoogdt, N., Hassanzadeh, G.G., Zhang, J., Brys, L., de Baetselier, P., Revets, H. (2003) Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proceedings of the National Academy of Sciences, 100(10): 5778-5782
Doumas, S., Kolokotronis, A., Stefanopoulos, P. (2005) Anti-Inflammatory and Antimicrobial Roles of Secretory Leukocyte Protease Inhibitor. Infection and Immunity, 73(3): 1271-1274
Fakioglu, E., Wilson, S.S., Mesquita, P.M.M., Hazrati, E., Cheshenko, N., Blaho, J.A., Herold, B.C. (2008) Herpes Simplex Virus Downregulates Secretory Leukocyte Protease Inhibitor: a Novel Immune Evasion Mechanism. Journal of Virology, 82(19): 9337-9344
Farquhar, C., Vancott, T.C., Mbori-Ngacha, D.A., Horani, L., Bosire, R.K., Kreiss, J.K., Richardson, B.A., John-Stewart, G.C. (2002) Salivary Secretory Leukocyte Protease Inhibitor Is Associated with Reduced Transmission of Human Immunodeficiency Virus Type 1 through Breast Milk. Journal of Infectious Diseases, 186(8): 1173-1176
Herrero, R., Castellsagué, X., Pawlita, M., Lissowska, J., Kee, F., Balaram, P. (2003) Human Papillomavirus and Oral Cancer: The International Agency for Research on Cancer Multicenter Study. JNCI: Journal of the National Cancer Institute, 95(23): 1772-1783
Hillbertz, N.S., Hirsch, J.M., Jalouli, J., Jalouli, M.M., Sand, L. (2012) Viral and molecular aspects of oral cancer. Anticancer Res, 32: 4201-4212
Hoffmann, M., Quabius, E.S., Tribius, S., Hebebrand, L., Görögh, T., Halec, G., Kahn, T., Hedderich, J., Röcken, C., Haag, J., Waterboer, T., Schmitt, M., Giuliano, A.R., Kast, M.W. (2013) Human papillomavirus infection in head and neck cancer: The role of the secretory leukocyte protease inhibitor. Oncology Reports, 29(5): 1962-1968
Jana, N.K., Gray, L.R., Shugars, D.C. (2005) Human Immunodeficiency Virus Type 1 Stimulates the Expression and Production of Secretory Leukocyte Protease Inhibitor (SLPI) in Oral Epithelial Cells: a Role for SLPI in Innate Mucosal Immunity. Journal of Virology, 79(10): 6432-6440
Jin, F., Nathan, C., Radzioch, D., Ding, A. (1997) Secretory Leukocyte Protease Inhibitor: A Macrophage Product Induced by and Antagonistic to Bacterial Lipopolysaccharide. Cell, 88(3): 417-426
Munadziroh, E. (2006) Roles of secretory leukocyte protease inhibitor amniotic membrane in oral wound healing. Dental Journal (Majalah Kedokteran Gigi), 39(4): 172-176
Nicol, A.F., Brunette, L.L., Nuovo, G.J., Grinsztejn, B., Friedman, R.K., Veloso, V.G., Cunha, C.B., Coutinho, J.R., Vianna, D.A.C., Oliveira, N.S., Woodham, A.W., da Silva, D.M., Kast, M.W. (2016) Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 73(1): 27-33
Nukiwa, T., Suzuki, T., Fukuhara, T., Kikuchi, T. (2008) Secretory leukocyte peptidase inhibitor and lung cancer. Cancer Science, 99(5): 849-855
Pierce-Campbell, C.M., Giuliano, A.R., Torres, B.N., O'Keefe, M.T., Ingles, D.J., Anderson, R.L. (2016) Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The Cancer Prevention Study II Nutrition Cohort. Oral Oncol, 55: 1-5
Quabius, E.S., Görögh, T., Fischer, G.S., Hoffmann, A.S., Gebhard, M., Evert, M., Beule, A., Maune, S., Knecht, R., Óvári, A., Durisin, M., Hoppe, F., Röcken, C., Hedderich, J., Ambrosch, P. (2015) The antileukoprotease secretory leukocyte protease inhibitor (SLPI) and its role in the prevention of HPV-infections in head and neck squamous cell carcinoma. Cancer Letters, 357(1): 339-345
Sand, L., Jalouli, J. (2014) Viruses and oral cancer. Is there a link?. Microbes and Infection, 16(5): 371-378
Sayers, K.T., Brooks, A.D., Sayers, T.J., Chertov, O. (2014) Increased Secretory Leukocyte Protease Inhibitor (SLPI) Production by Highly Metastatic Mouse Breast Cancer Cells. PLoS One, 9(8): e104223
Skeate, J.G., Porras, T.B., Woodham, A.W., Jang, J.K., Taylor, J.R., Brand, H.E., Kelly, T.J., Jung, J.U., da Silva, D.M., Yuan, W., Kast, M.W. (2016) Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. Journal of General Virology, 97(2): 422-434
Skott, P., Lucht, E., Ehnlund, M., Bjorling, E. (2002) Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism. Oral Diseases, 8(3): 160-167
Stępień, T., Brożyna, M., Kuzdak, K., Motylewska, E., Komorowski, J., Stępień, H., Ławnicka, H. (2017) Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer. Disease Markers, 2017: 1-5
Tse, K.P., Wu, C.S., Hsueh, C., Chang, K.P., Hao, S.P., Chang, Y.S., Tsang, N.M. (2012) The relationship between secretory leukocyte protease inhibitor expression and Epstein-Barr virus status among patients with nasopharyngeal carcinoma. Anticancer Res, 32(4): 1299-307
Wahl, S.M., McNeely, T.B., Janoff, E.N., Shugars, D., Worley, P., Tucker, C., Orenstein, J.M. (1997) Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-1. Oral Diseases, 3(S1): S64-S69
Westra, W.H. (2009) The Changing Face of Head and Neck Cancer in the 21st Century: The Impact of HPV on the Epidemiology and Pathology of Oral Cancer. Head and Neck Pathology, 3(1): 78-81
Zheng, D., Gui, B., Gray, K.P., Tinay, I.P., Rafiei, S., Huang, Q., Sweeney, C.J., Kibel, A.S., Jia, L. (2016) Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. Oncogene, 35(36): 4807-4815
 

O članku

jezik rada: srpski, engleski
vrsta rada: članak
DOI: 10.5937/asn1979936A
objavljen u SCIndeksu: 08.02.2020.
Creative Commons License 4.0